Dr Emily Bergsland is a Professor of Medicine and the Ernest Rosenbaum, MD, Endowed Chair in Medical Oncology at the University of California-San Francisco (UCSF). She has spent twenty years developing a clinical and research program focused on neuroendocrine tumours. Her clinical and research efforts are focused on advancing the care of patients with neuroendocrine neoplasms (NENs), understanding why NENs develop, and the development and testing of novel, biologically based therapies for NENs. Dr Bergsland is the Director of the University of California-San Francisco (UCSF) Centre for Neuroendocrine Tumours, Chair of the UCSF GI Oncology Site Committee and an active member of the Phase I Site Committee. Nationally, she is Chair of the Neuroendocrine Tumour Task Force of the National Cancer Institute (NCI) Gastrointestinal (GI) Steering Committee, a member of the NCCN Neuroendocrine Tumours Guidelines Panel, and is the current Vice-Chair (Chair-elect) of the North American Neuroendocrine Tumour Society (NANETS). She was also study chair for ALLIANCE A021202 (a randomized phase II trial of pazopanib v placebo in patients with progressive carcinoid tumours), a completed study which included a prospective plan for central review and archiving of serial radiologic images and blood sample collection for angiome profiling (analyses are pending).

Dr Emily Bergsland has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies: